Clinical Knowledge Base
Browse our latest clinical notes, summaries, and neurological strategies.
Neurological Bladder and Bowel dysfunction
Neurogenic bladder dysfunction (NGB) in conditions like Parkinson's disease and multiple sclerosis can cause urinary issues. Treatment includes antimuscarinic agents, intravesical oxybutynin, or botulinum toxin. Neurogenic bowel dysfunction (NBD) with constipation and incontinence in conditions like multiple sclerosis is managed with diet modification, laxatives, and, in severe cases, interventions like transanal irrigation or surgery.
Stiffperson Syndrome
Stiff-person syndrome (SPS) is a rare disorder characterized by progressive muscle stiffness and spasm, often associated with type 1 diabetes or, rarely, as a paraneoplastic syndrome. Treatment aims to control symptoms and improve mobility. Benzodiazepines like diazepam and clonazepam are commonly used. Baclofen may be considered if benzodiazepines are ineffective or intolerable. In refractory cases, IVIG, rituximab, or plasma exchange can be options for treatment.
Paramyotonia congenita
Paramyotonia congenita (PMC) is a non-progressive autosomal dominant disorder of skeletal muscles caused by SCN4A gene mutations. It leads to stiffness, worsened by cold or exertion. Treatment focuses on symptom management, including avoiding triggers, a low-potassium diet, and medications like mexiletine, lamotrigine, or acetazolamide. Genetic counseling is recommended.
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive genetic disorder with muscle weakness, cardiomyopathy, and respiratory problems. Multidisciplinary care, glucocorticoids, and genetic therapies are key treatments. Cardiomyopathy is managed with angiotensin receptor blockers, and respiratory issues require monitoring and interventions. Palliative care provides support at all stages.
Myotonic disorders
Myotonic disorders are genetic conditions causing clinical and electrical myotonia. Myotonia is characterized by delayed muscle relaxation after contraction and spontaneous muscle fiber discharge on EMG. It can be caused by various factors, including diseases and medications. Treatment includes avoiding triggers, symptomatic medications like mexiletine, and multidisciplinary care involving specialists in various fields. Physical therapy and orthoses can help manage muscle contractures, and palliative care can provide support throughout the disease course.
Myasthenic crisis
Myasthenic crisis is a life-threatening condition in myasthenia gravis with worsening weakness, often due to infection, surgery, or medications. Treatment includes intensive care, respiratory support, plasma exchange or IVIG, and immunomodulating therapy to improve strength and manage triggers.
Tick paralysis
Ticks can transmit infections to humans, causing tick paralysis due to neurotoxins. Symptoms start with paraesthesia and weakness, progressing to ascending paralysis and, in severe cases, respiratory failure and death. Treatment involves tick removal, and recovery typically occurs after removal. Supportive care may be needed for paralysis caused by certain tick species. Prevention includes wearing protective clothing and using tick repellents.
Inclusion body myositis
Inclusion body myositis (IBM) is an inflammatory muscle disorder with insidious onset of leg weakness and elevated serum CK. Treatment aims to optimize muscle strength and includes physical therapy, assistive devices, and immunosuppressive medications, particularly for those with associated autoimmune conditions or rapidly progressing weakness. Immune globulin and oxandrolone have unclear benefits and are not recommended.
Acid Maltase Deficiency
Acid Maltase Deficiency (Pompe disease) is a glycogen storage disease. It has infantile and late-onset forms. Infantile form presents with heart issues and can be fatal in early childhood. Late-onset form causes skeletal myopathy and respiratory problems. Newborn screening helps with early diagnosis. Treatment involves enzyme replacement therapy and multidisciplinary care.
Polymyalgia rheumatica
Polymyalgia rheumatica (PMR) causes pain and stiffness in shoulders, hips, and neck. Treatment uses low-dose glucocorticoids like prednisolone (initially 15 mg daily) with adjustments based on symptoms. Some stop treatment after 1-2 years, while adjunctive medications like methotrexate or tocilizumab may be added for comorbidities or glucocorticoid-related side effects. Physical therapy aids fitness recovery.
Dermatomyositis
Dermatomyositis (DM) is an inflammatory disorder with muscle weakness and characteristic skin manifestations. Treatment aims to improve muscle strength and resolve skin issues. Glucocorticoids are the initial therapy, followed by tapering. Glucocorticoid-sparing agents like azathioprine or methotrexate can be considered if steroids are ineffective. Skin symptoms can be managed with sun protection, topical treatments, and antihistamines. Intravenous immune globulin (IVIG) may help in severe cases with life-threatening weakness or dysphagia.
Botulism
Botulism is a serious condition caused by Clostridium botulinum bacteria, leading to cranial nerve symptoms and muscle weakness. Treatment involves hospitalization, respiratory support if needed, and antitoxin administration. For infants, human-derived botulism immune globulin is used. Foodborne botulism may require laxatives, wound botulism needs debridement and antibiotics.
Polymyositis
Polymyositis (PM) is an idiopathic inflammatory myopathy characterized by muscle weakness and inflammation. Treatment involves glucocorticoids, typically prednisolone or methylprednisolone, followed by tapering. Glucocorticoid-sparing agents like azathioprine or methotrexate may be considered if needed. Severe cases may benefit from intravenous immune globulin (IVIG). Physical therapy and dietary precautions are also important.
Tetanus
Tetanus is a disorder caused by Clostridium tetani, characterized by muscle spasms. Treatment involves wound management, neutralizing unbound toxin with human tetanus immune globulin (HTIG), and controlling spasms with diazepam or intrathecal baclofen. Autonomic dysfunction is managed with magnesium sulfate, labetalol, or morphine sulfate. Severe cases may require endotracheal intubation or tracheostomy, and nutritional support. Physical therapy helps with muscle recovery.
Lambert Eaton Syndrome
Lambert-Eaton Myasthenic Syndrome (LEMS) causes proximal muscle weakness and is associated with malignancies. Diagnosis involves CT scans and SOX antibody testing. Treatment options include amifampridine, guanidine, and pyridostigmine for mild cases. More severe cases may require immunomodifying treatments like IVIG, prednisolone, azathioprine, mycophenolate, or plasma exchange.
Myasthenia Ocular Type
Ocular Myasthenia Gravis (OMG) causes eye muscle weakness, resulting in ptosis and diplopia. Treatment options include acetylcholinesterase inhibitors, immunosuppressive therapy, thymectomy, and corrective surgeries for ptosis and strabismus. Immunomodulating treatments can be considered for refractory cases.
Periodic Paralysis
Periodic Paralysis (PP) is a neuromuscular disorder with different types, including hypokalemic PP, hyperkalemic PP, Andersen-Tawil syndrome, and thyrotoxic PP. Treatment varies based on the type and includes potassium supplementation, dietary changes, diuretics, and other medications as needed to manage and prevent attacks.
Episodic Ataxia
Episodic Ataxia (EA) encompasses seven types (EA1 through EA7) with varying symptoms. EA1 and EA2 are common, featuring myokymia, ataxia, and more. Triggers include stress, activity, and more. Treatment options include acetazolamide, carbamazepine, dalfampridine, and levetiracetam depending on the type.
Parkinsons disease DBS
Deep Brain Stimulation (DBS) is used for severe Parkinson's motor symptoms. It's safe and reversible, targeting brain regions with implanted electrodes. Risks include infection and hardware issues. Long-term benefits include improved rigidity, tremor, and motor fluctuations, but bradykinesia improvement may decline.
Parkinsons disease Apomorphine usage
Apomorphine is a potent dopamine agonist used for sudden "off" periods in Parkinson's disease. It can be administered subcutaneously or sublingually. Subcutaneous injection requires premedication, close monitoring, and ECG. Sublingual absorption bypasses metabolism but may cause side effects. Continuous subcutaneous infusion (CSAI) is an option with potential side effects, including skin nodules and hematological issues. Regular monitoring is necessary for safety.
Parkinsons disease Gel Infusion protocol
Levodopa-carbidopa intestinal gel (LCIG) is used for Parkinson's disease to reduce motor fluctuations. It's delivered via a tube with a battery-powered pump. Vitamin B12 levels should be monitored, and patients may need additional oral levodopa at night if "wearing off" occurs. Precautions include potential adverse events and tube maintenance.
Parkinsons disease Freezing episodes
Freezing of gait in Parkinson's disease can be managed by adjusting levodopa doses during "off" periods and using non-pharmacological strategies like physical therapy. Medications like methylphenidate and amantadine may help. Investigational therapies like dopaminergic cell transplantation show promise.
Parkinsons disease Falls
Falls in Parkinson's disease can be prevented through regular assessment and risk evaluation. Tools like the POMA score assess balance and gait. Treating freezing of gait and postural hypotension is crucial. Deep brain stimulation may help in advanced cases.
Parkinsons disease Sleep disorders
Sleep disorders in Parkinson's disease, including insomnia and excessive daytime sleepiness, can impact patients' quality of life. Management involves education, light therapy, exercise, and medication adjustments. Restless leg syndrome may require lifestyle changes and medication.
Parkinsons disease GI disorders
Gastrointestinal issues are common in Parkinson's disease, including nausea, vomiting, dysphagia, reflux, and constipation. Managing these symptoms involves various approaches, including medication adjustments, dietary modifications, and rehabilitation therapy to improve the patient's quality of life. Sialorrhea and drooling are also prevalent and can be addressed through appropriate measures.
Parkinsons disease Dysautonomia
Autonomic neuropathy in Parkinson's disease can manifest with symptoms like constipation, postural hypotension, rhinorrhea, sexual dysfunction, and sialorrhea. Management includes various strategies and medications to address these issues, with a focus on improving the patient's quality of life.
Parkinsons disease Psychiatric issues
Psychiatric and behavioral disorders in Parkinson's disease may include visual hallucinations, delusions, and depression. Managing psychosis involves identifying underlying causes, adjusting antiparkinson medications, and considering antipsychotic agents like quetiapine, clozapine, or pimavanserin. These drugs have specific dosing considerations and potential side effects.
Parkinson disease Cognitive impairment
Cognitive impairment in Parkinson's disease can manifest as executive dysfunction, visuospatial difficulties, or memory deficits. Treatment options include cholinesterase inhibitors (e.g., rivastigmine, donepezil) and memantine. Cholinesterase inhibitors may have mild benefits but can cause side effects, while memantine's effectiveness needs further confirmation.
Parkinsons disease Levodopa Induced Dyskinesia
NULL
Parkinsons disease Akinetic attacks
Acute akinesia is a sudden worsening of Parkinson's disease characterized by immobility lasting several days. It often responds poorly to standard Parkinson's medications and can be lethal. It's important to identify and address underlying causes, such as infection or medication errors, in hospitalized patients.
Parkinsons disease Diphasic Dyskinesia
Diphasic dyskinesia, characterized by two peaks of dyskinesia after levodopa doses, can be challenging to manage. Strategies include adjusting levodopa dosing, adding dopamine agonists, and considering infusion therapies or surgeries if other options fail.
Parkinsons disease Wearing off Phenomena
Long-term levodopa use in Parkinson's disease can result in "wearing off" motor fluctuations. Strategies include dietary changes, dose adjustments, long-acting formulations, and adjunctive therapies like dopamine agonists, MAOB inhibitors, COMT inhibitors, and istradefylline. Rescue options are also available.
Parkinsons disease Peak dose Dyskinesia
Dyskinesia, often due to excessive dopamine stimulation, occurs after levodopa intake. Treatment options include adjusting levodopa dosing, using amantadine, or considering adjunctive therapies like low-dose clozapine. Some patients prefer living with dyskinesia.
Parkinsons disease Recurrent Off periods
Effective treatments for reducing "off" periods in Parkinson's disease include carbidopa/levodopa enteral suspension (Duopa), levodopa inhalation powder, sublingual apomorphine film, and add-on medications like safinamide and istradefylline, all of which have demonstrated significant improvements in managing off-periods.
Parkinsons disease Basic Management
Parkinson's disease treatment involves non-pharmacological approaches like exercise, occupational therapy, and nutrition. Tai chi and yoga have shown benefits. Pharmacological options include levodopa, dopamine agonists, MAOB inhibitors, amantadine, and anticholinergic drugs, each with considerations. Surgery may be considered for certain cases, such as DBS.
Serotonin Syndrome
Serotonin syndrome, potentially life-threatening, results from excess serotonergic activity. Caused by drug interactions or self-poisoning, it exhibits altered mental state, hyperactivity, and neuromuscular issues. Treatment involves discontinuing agents, supportive care, benzodiazepines, serotonin antagonists, and sometimes paralysis and intubation.
Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome (NMS) is a life-threatening condition associated with antipsychotic drugs. It presents with altered mental status, fever, rigidity, and dysautonomia. Treatment includes stopping the causative agent, supportive care, medications like dantrolene, bromocriptine, amantadine, benzodiazepines, and, in severe cases, electroconvulsive therapy (ECT). Restarting antipsychotics should be done with caution and expert guidance, starting with low doses of lower-potency agents while monitoring for NMS symptoms, and avoiding concomitant lithium and dehydration.
Tic Disorders
Tics, common in Tourette syndrome (TS), are managed with education, behavioral therapy (HRT), and medications like VMAT2 inhibitors, antipsychotics, alpha adrenergic agents, or topiramate. Severe cases may benefit from deep brain stimulation (DBS). Comorbid conditions like ADHD and OCD may require SSRIs, alpha adrenergic agonists, or CNS stimulants.
Hemichorea
Hemichorea is characterized by one-sided involuntary movements and can result from various causes. Treatment depends on the underlying condition and may involve addressing the cause, withdrawing medications, using dopamine blockers, VMAT2 inhibitors, or other medications. In severe cases, surgical options like DBS may be considered.
Chorea
Chorea is a hyperkinetic movement disorder with various causes. Treatment depends on the underlying condition. In Huntington's disease, dopamine depleting agents like tetrabenazine are used. Other treatments include antipsychotics and surgical options. Chorea in Sydenham chorea may be treated with antibiotics and chorea-suppressing medications. Wilson's disease is managed with copper-chelating agents and zinc acetate.
Essential Tremor
Essential Tremor (ET) is a common cause of action tremor. Mild cases may not require treatment, while intermittent symptoms may be managed with drugs like propranolol or primidone. Severe and drug-resistant cases may benefit from surgical options like deep brain stimulation or thalamotomy.
Dystonia new
Dystonia is an extrapyramidal disorder characterized by repetitive muscle contractions leading to abnormal postures and movements. Treatment includes non-pharmacological approaches, various oral medications, botulinum toxin injections, and deep brain stimulation for severe cases.
Dopa Responsive Dystonia
Dopa Responsive Dystonia (DRD), resembling juvenile Parkinson's, is effectively treated with Levodopa, typically 100-750 mg daily, either alone or with carbidopa. This treatment provides long-term symptom relief without motor complications. Ineffectiveness of Levodopa warrants reevaluation of the diagnosis.
Dyskinesias
Dyskinesias include acute dyskinesia from dopamine blockers in Parkinson's, tardive dyskinesia from prolonged anti-dopaminergic use, peak dose dyskinesia in Parkinson's due to Levodopa, spontaneous dyskinesia in the general population, and Meige syndrome (cranial dystonia), treatable with zolpidem. Management varies based on the type and cause.
Tardive Dyskinesia
Tardive dyskinesia, a result of long-term anti-dopaminergic medication use, is treated by discontinuing the causative agent, switching to safer antipsychotics, and using VMAT2 inhibitors, botulinum toxin, benzodiazepines, anticholinergics, or amantadine. Deep brain stimulation is considered for severe, treatment-resistant cases.
Antimyelin Oligodendrocyle Glycoprotein Demyelination
MOG antibody-related disorders, linked to demyelinating conditions like ADEM and NMOSD, are diagnosed by serum MOG-IgG positivity and CNS symptoms. Prognosis is generally favorable. Treatment includes high-dose methylprednisolone for acute attacks, and immunotherapies like mycophenolate or rituximab for relapsing cases to reduce frequency.
Chronic Relapsing Inflammatory Optic Neuropathy
Chronic Relapsing Inflammatory Optic Neuropathy (CRION) is a rare autoimmune optic neuritis, distinct from conditions like sarcoidosis, lupus, MS, or NMO. Diagnosed through MRI and exclusion of other causes, CRION treatment requires long-term immunosuppression, as glucocorticoid tapering often leads to relapse. Effective treatments include azathioprine, methotrexate, cyclophosphamide, and IVIG.
Acute Transverse Myelitis
Acute Transverse Myelitis, causing spinal cord inflammation, is treated with high-dose intravenous glucocorticoids and plasma exchange for severe cases. Cyclophosphamide may be beneficial, and treatment for secondary TM focuses on the underlying condition. Recurrent TM is managed with immunomodulatory therapies like mycophenolate or rituximab.
Neuromyelitis Optica
NMOSD, distinct from MS, is marked by AQP4 antibodies causing optic neuritis and myelitis. Diagnosis involves specific clinical criteria and antibody presence. Treatment includes methylprednisolone, plasma exchange, and immunotherapies like eculizumab and rituximab. Refractory cases may benefit from azathioprine or mycophenolate mofetil, with therapy typically lasting five years.
PML and JCV titers
Progressive multifocal leukoencephalopathy (PML), caused by John Cunningham virus reactivation, often follows immunomodulatory therapy or HIV. It presents with neurological deficits, diagnosed via MRI and lumbar puncture. Treatment focuses on restoring immune response, especially effective antiretroviral therapy in HIV. Prognosis is generally poor, with high mortality.
Multiple sclerosis Spasticity and Pain
Spasticity in MS, manifesting as resistance to movement or involuntary jerks, is managed with physiotherapy, exercises, and medications like baclofen and tizanidine. MS-associated pain, including trigeminal neuralgia and neuropathic pain, is treated with carbamazepine, gabapentin, pregabalin, and amitriptyline, tailored to the specific pain syndrome.
Multiple sclerosis Cognition and Ambulation issues
Cognitive impairment in MS, manifesting as inattention and memory issues, is managed with coping strategies, cognitive rehabilitation, and treating associated conditions like sleep disorders. Gait impairment is addressed through physical therapy, mobility aids, and possibly dalfampridine. Some DMTs may modestly benefit cognitive function.
Multiple sclerosis Bladder and Bowel issues
In MS, neurogenic bladder dysfunction causes urinary frequency and urgency, often worsened by infections. Treatment includes Oxybutynin for overactivity and Tamsulosin for sphincter dyssynergia, with botulinum toxin and neuromodulation as alternatives. Bowel issues are managed with diet, laxatives, and enemas, and severe faecal incontinence may require surgery.
Multiple sclerosis Tysabri protocol and monitoring
Natalizumab, given as a 300 mg IV infusion every four weeks, can cause infusion reactions, infections, melanoma, liver toxicity, and PML. Monitoring includes blood tests, JCV index, MRI, and TB screening. Discontinue for severe side effects, PML, lack of efficacy, or active disease. Extended dosing intervals may reduce PML risk.
Multiple sclerosis Tecfidera protocol and monitoring
Dimethyl fumarate, initially dosed at 120 mg twice daily and then increased to 240 mg, may cause flushing, gastrointestinal issues, lymphopenia, PML, and liver toxicity. Pre-treatment checks include blood tests, urinalysis, and MRI. Ongoing monitoring involves blood counts, liver function, and annual MRI. Discontinuation is advised for significant liver injury.
Multiple sclerosis Ocrevus protocol and monitoring
Ocrelizumab, used for B cell depletion, has risks of infusion reactions, infections, and lymphopenia. It's contraindicated in active hepatitis and post-live vaccines. Premedication and thorough pre-therapy assessments, including MRIs and blood tests, are essential. Ongoing monitoring involves blood tests, immune status, and annual MRIs.
Complex regional pain syndrome - 2
CRPS Type II, following nerve injury, often affects upper limbs, causing burning pain and hyperalgesia. Treatment involves a multidisciplinary approach with physical therapy, medications like NSAIDs and antidepressants, and bisphosphonates for specific cases. Interventional procedures are used for refractory cases. Prognosis varies; vitamin C may help prevent recurrence.
Complex regional pain syndrome - 1
Complex Regional Pain Syndrome (CRPS), often post-injury, involves sensory, autonomic, and motor symptoms. Treatment, ideally multidisciplinary and early, includes physical therapy, medication like NSAIDs or gabapentin, and bisphosphonates for specific cases. Refractory CRPS may require interventional pain management. Prognosis varies, with potential recurrences preventable by vitamin C.
Thalamic Pain Syndrome
Thalamic Pain Syndrome, often post-stroke, manifests with delayed neuropathic pain, temperature sensitivity, and hyperalgesia. Treatment requires a multidisciplinary approach and includes medications like amitriptyline, trazodone, venlafaxine, gabapentin, or opioids. Refractory cases may need invasive interventions like deep brain stimulation.
Multiple sclerosis Betaseron protocol and monitoring
Interferon beta-1b for MS is given subcutaneously every other day, with dose titration. Common side effects include flu-like symptoms, liver dysfunction, and blood cell changes. Monitoring involves regular blood tests, liver function, and neutralizing antibodies. Adjust or discontinue for severe side effects or pregnancy.
Multiple sclerosis Avonex protocol and monitorin
Interferon beta-1a is administered intramuscularly weekly for MS, starting with a quarter dose, increasing to 30 μg. Side effects include flu-like symptoms, liver dysfunction, and blood cell changes. Monitoring involves regular blood tests, liver function, and checking for neutralizing antibodies. Discontinue for severe side effects or pregnancy.
Multiple sclerosis SPMS Management
For Secondary Progressive MS (SPMS), active disease management involves switching to treatments like Siponimod or Ocrelizumab. In cases with low activity, continuing or changing to Siponimod is advised, while discontinuation may be considered for inactive SPMS. Refractory cases might benefit from Cladribine, stem cell transplantation, or Methylprednisolone for acute attacks, tailored to individual responses and disease activity.
Multiple_sclerosis_PPMS_Criteria
Primary Progressive MS (PPMS) constitutes about 10% of MS cases and is characterized by a gradual increase in disability, often presenting as spinal cord syndrome. Diagnosed based on patient history and the McDonald criteria, it requires evidence of one-year progression and two out of three indicators: specific MRI lesions and cerebrospinal fluid oligoclonal bands. PPMS affects both genders equally, typically beginning around age 40.
Multiple sclerosis RRMS When to change disease modifying therapy
Changing Disease Modifying Therapy (DMT) in RRMS is considered for poor response, adherence issues, side effects, pregnancy, or COVID-19 risks. Alternatives are chosen based on the individual's response, with factors like JC Virus status and pregnancy affecting decisions. Some DMTs, particularly those causing lymphopenia, may heighten COVID-19 infection risks.
Multiple sclerosis RRMS Role of antibodies and MRIs for monitoring
Monitoring the response to Disease Modifying Therapies in Relapsing Remitting MS involves periodic MRIs to assess lesion progression and brain atrophy, and testing for specific autoantibodies like AQP4 and MOG-IgG. MRI is crucial for tracking new lesions and atrophy, while autoantibodies indicate specific disease aspects. Oligoclonal bands and CHI3L1 levels in CSF also provide prognostic information.
Multiple sclerosis RRMS Choice of Initial Disease modifying Drugs
Disease Modifying Therapies (DMT) for Relapsing Remitting MS (RRMS) include oral agents (dimethyl fumarate, teriflunomide), infusion therapies (natalizumab, ocrelizumab), and injections (interferon beta, glatiramer). Selection depends on disease severity, side effects, and patient preference. Oral agents are easy to use but require safety monitoring, while infusions target active disease but have higher risk profiles. Injections are safer but less potent. Treatment usually continues indefinitely.
Multiple sclerosis RRMS Latest Diagnostic criteria
Relapsing-remitting MS (RRMS) is diagnosed clinically, typically presenting in young adults with episodes of CNS dysfunction, such as vision loss or limb weakness. MRI reveals characteristic hyperintense white matter lesions. The McDonald criteria aid diagnosis, requiring evidence of multiple attacks and lesions. Additional tests like CSF oligoclonal bands, visual evoked potentials, optical coherence tomography, and autoantibody tests for AQP4 and MOG are used when presentations are atypical or insufficiently conclusive.
Multiple sclerosis Basic Management
Multiple Sclerosis, an immune-mediated CNS disease, has no cure but treatments delay progression. Relapsing-remitting MS is managed with oral, infusion, and injection therapies. Secondary progressive MS involves switching treatments, with options like siponimod. Primary progressive MS is treated with ocrelizumab, especially in younger patients. Acute attacks are managed with high-dose methylprednisolone.
Vasculitic neuropathies
Vasculitic neuropathies, part of systemic vasculitis affecting various organs, present with acute, painful neuropathy and sensory deficits. Treatment targets the underlying condition with immunosuppressants like glucocorticoids or cyclophosphamide and symptom management. Pain is managed with drugs like pregabalin. Rehabilitation and monitoring through neurological exams are crucial for detecting and managing relapses.
Peripheral neuropathy
Peripheral neuropathy encompasses polyneuropathy, radiculopathy, and mononeuropathy, often presenting with symmetrical distal sensory loss, burning sensations, or motor weakness. Common causes include diabetes, renal impairment, amyloidosis, alcohol abuse, HIV, and certain medications. Treatment focuses on managing the underlying disease and symptom relief. Medications like gabapentin, duloxetine, pregabalin, and carbamazepine are used for symptom control, sometimes alongside tramadol, NSAIDs, or narcotics for pain. Severe cases may require surgical interventions like epidural injections. Physical therapy, foot care, and use of orthoses are important for lifestyle improvement and preventing complications like foot ulcers.
Multifocal motor neuropathy
Multifocal motor neuropathy (MMN) is a rare, slowly progressive disease characterized by asymmetric weakness and atrophy, predominantly in the arms and hands, without sensory loss. Often associated with anti-GM1 antibodies, MMN leads to disability if untreated. Treatment primarily involves intravenous immune globulin (IVIG), with maintenance infusions every two to six weeks. Alternatives like cyclophosphamide or rituximab have limited efficacy. Rehabilitation focuses on limb positioning, posture, orthotics, and exercise programs for fatigue management.
Miller Fisher syndrome
Miller Fisher syndrome, characterized by ophthalmoplegia, ataxia, and areflexia, often involves antibodies against GQ1b in 85-90% of cases. Its electrodiagnostic features include reduced or absent sensory responses without sensory conduction velocity slowing. Frequently linked to infections like Campylobacter jejuni or Epstein-Barr virus, MFS treatment aligns with Guillain-Barré syndrome, primarily involving plasmapheresis and intravenous immune globulin (IVIG).
Chronic inflammatory demyelinating polyneuropathy
Polyneuropathy encompasses various immune-mediated neuropathies, including Guillain-Barré syndrome (acute) and chronic inflammatory demyelinating polyneuropathy (CIDP). Other types include CIDP variants, multifocal motor neuropathy, conditions like MGUS, POEMS syndrome, neuropathy with IgM gammopathy, and Waldenström macroglobulinemia. Also involved are mixed cryoglobulinemia syndrome, GALOP syndrome, CANOMAD syndrome, primary amyloidosis, paraneoplastic neuropathies, and neuropathies associated with systemic autoimmune diseases. These present with diverse sensory, motor, or autonomic symptoms, and treatment is typically specific to the underlying cause.
Guillain Barré syndrome
Guillain-Barré syndrome (GBS) is characterized by progressive muscle weakness and diminished reflexes. Key treatment includes plasma exchange or IVIG, and supportive care in ICU or wards is crucial, focusing on respiratory, cardiac, and hemodynamic monitoring. Autonomic dysfunction and pain management are also critical aspects of care. Rehabilitation plays a vital role, and although relapses occur in some patients, treatment options for these cases are less clear.
Infectious neuropathy
The article outlines different neuropathic syndromes related to HIV and other infectious diseases. It emphasizes the prevalence of distal symmetric peripheral neuropathy (DSPN) in HIV patients, attributing it to factors like age, duration of HIV infection, and certain medications. Treatment for HIV-related neuropathy includes Antiretroviral therapy (ART), addressing reversible risk factors, and symptom management with medications like Gabapentin, duloxetine, venlafaxine, nortriptyline, and topical capsaicin cream.
Polyneuropathy
The article discusses various types of immune-related neuropathies. It begins with an overview of polyneuropathy, dividing it into acute (Guillain-Barré syndrome) and chronic forms (like chronic inflammatory demyelinating polyneuropathy). It then details specific neuropathies such as multifocal motor neuropathy, monoclonal gammopathy, POEMS syndrome, and others like Waldenström macroglobulinemia and mixed cryoglobulinemia syndrome. Each type is described in terms of symptoms, diagnosis, and treatment, highlighting their unique characteristics and management strategies.
Bell's palsy
Bell's palsy, the most common cause of acute spontaneous peripheral facial paralysis, is believed to involve inflammation and edema of the facial nerve, possibly related to herpes simplex virus reactivation. While most patients recover within several months to a year, up to a third experience chronic facial weakness, impacting function and appearance. Treatment primarily involves early short-term oral glucocorticoids, like prednisolone, and in severe cases, antiviral therapy with agents such as valacyclovir or acyclovir
Brachial plexitis
Brachial plexitis, which can be acute or gradual in onset, typically presents with shoulder or upper arm pain, and sometimes progressive numbness or muscle weakness. It is associated with various conditions including diabetes, inflammation (neuralgic amyotrophy), malignancies like lung and breast cancer, post-radiation, or trauma. Diagnosis is aided by nerve conduction studies and electromyography. Management generally involves conservative approaches, with physical therapy being central to alleviating pain, improving functionality, and maintaining range of motion. Treatment techniques include electrical nerve stimulation and cryotherapy. Pain relief is primarily achieved using non-steroidal anti-inflammatory drugs like naproxen, and in some cases, adjunctive therapies like glucocorticoids or narcotics for severe pain are employed.
Spinobulbar muscular atrophy
Spinobulbar muscular atrophy (Kennedy disease [KD]) is an X-linked disorder, typically manifesting between ages 20-60.
Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by the progressive weakening and atrophy of muscles due to the degeneration of neurons in the spinal cord and lower brainstem. It presents in various forms, from prenatal onset to late adult onset, with symptoms including muscle weakness predominantly in the lower limbs, respiratory insufficiency, and normal cognitive function. Treatment for SMA involves supportive care to manage nutritional and respiratory needs, physical therapy, and potentially spinal bracing or surgery for scoliosis. Disease-modifying therapies like nusinersen and onasemnogene abeparvovec are used, alongside genetic counseling for affected individuals and their families.
Primary Lateral Sclerosis
Primary Lateral Sclerosis (PLS) is a neurodegenerative disease characterized by a slower progression compared to Amyotrophic Lateral Sclerosis (ALS) and primarily affects upper motor neurons. Its symptoms, which typically begin in the lower extremities, include spasticity, hyperreflexia, bladder instability, and urinary retention. Treatment for PLS, which lacks disease-modifying options, focuses on improving mobility and reducing spasticity through a combination of physical therapy, assistive devices, and medications like baclofen, tizanidine, and clonazepam. Management benefits from a multidisciplinary approach, similar to ALS care, but Riluzole, commonly used in ALS, has not shown significant benefits for PLS.
Amyotrophic Lateral Sclerosis
This article provides a comprehensive overview of Amyotrophic Lateral Sclerosis (ALS), a degenerative motor neuron disease characterized by symptoms like hyperreflexia, spasticity, and limb weakness. It emphasizes the need for a multidisciplinary management approach involving various healthcare professionals. The article details treatments like riluzole, edaravone, and investigational therapies, along with their dosages and side effects. It also discusses experimental therapies, symptom management strategies for respiratory issues, dysphagia, muscle spasms, fatigue, and pseudobulbar affect, and underscores the importance of palliative and hospice care.
Postural tachycardia syndrome
Postural tachycardia syndrome (POTS) is characterized by an excessive increase in heart rate upon standing and can cause symptoms like lightheadedness and palpitations. It may be caused by genetic or acquired factors such as hypovolemia or kidney issues. Diagnosis involves a significant heart rate increase upon changing posture. Non-pharmacological measures like hydration and exercise are helpful. Medications like fludrocortisone, midodrine, pyridostigmine, and propranolol can be used for treatment.
Orthostatic hypotension
Orthostatic hypotension, a drop in blood pressure upon standing, can result from various causes like diabetes or medications. Symptoms include dizziness and fainting. Non-drug measures like exercise and proper hydration are first-line treatments. If necessary, medications like fludrocortisone or pressor agents such as midodrine and droxidopa may be prescribed for moderate to severe cases. Second-line treatments like erythropoietin, caffeine, and pyridostigmine may also be considered but have limited evidence of effectiveness.
Transient global amnesia
Transient global amnesia (TGA) is a sudden memory loss condition, usually resolving within 24 hours. Its causes can vary. Diagnostic evaluation involves a neurological exam and brain MRI. No specific treatment is needed, but reassurance is important, and driving restrictions may apply during recurrent episodes. Stroke risk factors may be managed based on specific findings.
Status Epilepticus
Status epilepticus is a medical emergency characterized by prolonged seizures. It has serious long-term consequences, including injury and death. Treatment involves three phases: assessment and supportive care, initial benzodiazepine treatment, and long-term nonbenzodiazepine antiseizure drug therapy. Various drugs like lorazepam, diazepam, fosphenytoin, phenytoin, valproate, and levetiracetam can be used in these phases. In refractory cases, alternative agents like lacosamide, topiramate, and midazolam, propofol, or pentobarbital infusions may be considered, but the prognosis remains poor. Focal and myoclonic status epilepticus follow similar principles of treatment.
Refractory epilepsy
Refractory epilepsy, affecting 20% of patients, doesn't respond to two tolerated antiseizure drugs. Diagnosis involves brain MRI and video-EEG monitoring. Resective epilepsy surgery is the main curative option, while other approaches offer palliative relief. Surgery is most effective when the focus is consistently identified. Further antiseizure drug treatment, selecting different drugs or combinations, and participating in clinical trials are alternative options for management.
Absence seizures
Absence seizures, typically seen in children, are characterized by brief episodes of staring, eye blinking, and lip smacking lasting 5 to 10 seconds. Myoclonic seizures involve sudden muscle contractions. First-line treatment for absence seizures is ethosuximide, with a typical starting dose of 5-10 mg/kg/day for younger children and 250 mg twice daily for older children. Valproate or lamotrigine can be considered if ethosuximide is ineffective or not tolerated. Carbamazepine, vigabatrin, tiagabine, gabapentin, phenytoin, and phenobarbital should be avoided. Seizures often respond well to treatment, and drug therapy may be tapered after a minimum of two years of seizure-free intervals.
Epilepsy
Epilepsy is diagnosed when a person experiences two or more unprovoked seizures occurring over 24 hours apart. It encompasses various seizure types, including generalized tonic-clonic, absence, myoclonic, tonic, and atonic seizures, with causes ranging from genetic factors to structural, metabolic, immune, and unknown factors. Treatment primarily involves antiseizure drugs, with approximately 50% of patients achieving seizure freedom on their initial medication. Initial drug selection considers factors like efficacy, side effects, drug interactions, and patient preferences, and treatment should include patient education on medication compliance and side effect monitoring.
First time seizure
Seizures can be generalized or focal, with various subtypes. Initial evaluation includes history, lab tests, and neuroimaging, primarily for loss of consciousness. Not all seizures need medication; it depends on recurrence risk and causes. Hospitalization may be necessary in certain cases. Decisions on starting medication after a first seizure depend on factors like abnormal neurological findings and EEG results. Patients should be aware of triggers and activities to avoid, especially regarding driving. Common antiseizure drugs include levetiracetam, phenytoin, and valproic acid, with regular monitoring for side effects and drug levels.
Restless legs syndrome
Restless legs syndrome (RLS) is a treatable sleep disorder causing leg discomfort and an irresistible urge to move the legs. Treatment includes lifestyle changes, iron therapy for low iron levels, and medications like dopamine agonists or alpha-2-delta calcium channel ligands. Augmentation, a worsening of symptoms with medication, can be managed by adjusting treatment. Refractory cases may require combining medications or using low-dose opioids. Treatment should be tailored to the individual, with careful monitoring for effectiveness and side effects.
Nocturnal enuresis
Nocturnal enuresis (NE) refers to bedwetting in adults, often associated with various medical conditions and medications. It can lead to psychological distress. Treatment options include addressing underlying medical issues, lifestyle changes (avoiding certain substances, weight management, regular exercise), behavioral therapy (timed voiding, alarm systems, adapted dry behavioral therapy), and medications like desmopressin or imipramine. For resistant cases, neuromodulation or botulinum toxin injections may be considered after other modalities have failed.
Sleep related hallucinations
Hypnagogic and hypnopompic hallucinations are vivid sensory experiences occurring during sleep transitions. They can be linked to various conditions and medications. Treatment primarily addresses daytime sleepiness and cataplexy, which can indirectly improve hallucinations. Non-pharmacological approaches include sleep hygiene and napping. Medications like modafinil, armodafinil, solriamfetol, and others are used to manage symptoms, while REM sleep-suppressing drugs like venlafaxine or sodium oxybate may also be considered.
Recurrent isolated sleep paralysis
Recurrent isolated sleep paralysis (RISP) involves temporary immobility and hallucinations during sleep transitions. It affects about 20% of young adults, often linked to anxiety or sleep deprivation. Treatment includes education, sleep hygiene, and cognitive-behavioral therapy (CBT). Tricyclic antidepressants or selective serotonin reuptake inhibitors can be used to reduce episodes.
Rapid Eye Movement
Rapid Eye Movement (REM) sleep behavior disorder (RBD) involves acting out dreams during REM sleep and is associated with potential injury to oneself or a bed partner. It is often a precursor to neurodegenerative conditions like Parkinson's disease. Treatment focuses on creating a safe sleeping environment, which can include behavioral modifications such as separate beds or rooms and removing potential hazards. Medications like melatonin or clonazepam may be prescribed when necessary, especially in cases with frequent or disruptive behaviors that pose a risk.
Nightmare disorder
Nightmares, often triggered by stress or trauma, can disrupt daily life. Lifestyle adjustments, such as emotional well-being, avoiding specific substances before bedtime, and maintaining a regular sleep schedule, can alleviate symptoms. Psychotherapy, particularly imagery rehearsal therapy (IRT), is effective for managing recurring nightmares by rewriting and rehearsing them to make them less distressing. When medication is needed, prazosin, an alpha-1 adrenergic receptor antagonist, is a common choice.
Sleep terrors
Sleep terrors involve sudden sitting up in bed, screaming, and sometimes walking around during non-REM sleep. They typically happen early in the night and can last for a few minutes to 40 minutes. These episodes are often associated with increased sympathetic nervous system activity and may be seen in individuals with psychiatric conditions like PTSD or anxiety. Treatment includes behavioral strategies like avoiding sleep deprivation and alcohol, as well as educating family members on how to safely interact during episodes. In severe cases, medications like clonazepam may be used.
Sleepwalking (somnambulism)
Sleepwalking (somnambulism) involves complex behaviors like walking or rearranging furniture during sleep, often with amnesia. Prevention includes maintaining regular sleep schedules, a safe sleep environment, and sometimes cognitive-behavioral therapy. Medications like clonazepam or melatonin are reserved for severe cases. Safety education is essential to avoid injury during episodes.
Non-24-hour sleep-wake rhythm disorder
Non-24-hour sleep-wake rhythm disorder (
Advanced sleep-wake phase disorder
Advanced sleep-wake phase disorder (ASWPD) causes early sleep onset and wake times, resulting in daytime sleepiness. Evening bright light therapy, where patients sit near a bright light for 1-3 hours, is the main treatment. Behavioral methods like chronotherapy can help. Melatonin might be considered but lacks strong evidence, while hypnotics for early morning awakening should be avoided due to potential daytime drowsiness.
Delayed sleep-wake phase disorder
Delayed sleep-wake phase disorder (DSWPD) is common in adolescents, causing them to stay up and wake later than desired, often leading to difficulties in daily life. Comorbid depression is also frequent. Treatment mainly involves behavioral changes, like gradually adjusting bedtime and wake time, improving sleep hygiene, and avoiding stimulants before sleep. In cases where these don't work, timed melatonin or light therapy may help realign the circadian rhythm. Melatonin (3 mg before bedtime) can be tried, and morning light exposure can be used to shift the circadian rhythm earlier. It's crucial for patients to follow these therapies consistently.
Idiopathic
Idiopathic hypersomnia causes chronic excessive daytime sleepiness and difficulty waking up. Diagnosis requires polysomnography to rule out other causes. Treatment focuses on symptom management. Non-pharmacological approaches like lifestyle advice and behavioral modification are recommended, but they may not be very effective. Medications like modafinil, armodafinil, or methylphenidate can help control sleepiness, but patients should be cautious with activities like driving. Regular follow-ups every six months are important to monitor medication effects and overall well-being.
Narcolepsy
Narcolepsy is characterized by daytime sleepiness, cataplexy, hallucinations, and sleep paralysis. Diagnosis involves sleep tests. Treatment may include non-pharmacological measures like sleep hygiene and support groups. Medications like modafinil, armodafinil, solriamfetol, pitolisant, or stimulants can help with daytime sleepiness. Cataplexy may require drugs like venlafaxine or sodium oxybate. Patients should also be screened for depression and treated if necessary.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is common in obese men and characterized by symptoms like snoring and gasping during sleep. Diagnosis is confirmed through polysomnography. Treatment includes behavioral changes, such as weight loss and positional adjustments, and positive airway pressure therapy like CPAP. In severe cases, oral appliances or surgery may be considered. Patients should also be aware of the risks associated with untreated OSA, including daytime sleepiness and an increased risk of accidents.
Insomnia
Insomnia can occur due to multiple factors, both short-term and chronic. Short-term cases may require short-term medication, while chronic insomnia can be managed with Cognitive and Behavioral Therapy (CBT) or medication like zolpidem. Tapering medication and addressing sleep expectations are crucial. CBT includes behavioral and cognitive components, and medication choice varies. Efforts to discontinue sedative medications and reinforce healthy sleep habits through CBT are essential for long-term management.
Lyme disease
Lyme disease can affect the nervous system, causing facial nerve palsy, meningitis, and radiculoneuritis. Diagnosis relies on positive Lyme serologies. Treatment varies based on the neurological manifestation. For facial palsy, oral doxycycline is common. Meningitis and radiculoneuritis may need intravenous antibiotics like ceftriaxone. Lack of response may have various causes and requires reevaluation. Prophylaxis with doxycycline is recommended for specific tick bite situations.
Behçet's syndrome
Behçet's syndrome is characterized by recurrent oral and genital ulcers, along with various systemic manifestations. Neurological issues are rare but can affect the brain tissue or dural sinuses. Treatment depends on severity, with immunosuppressive drugs like azathioprine used for severe cases. Dural sinus thrombosis may require anticoagulation therapy.
Whipple’s disease
Whipple's disease (WD) is caused by T. whipplei bacteria and can affect the central nervous system (CNS). Symptoms vary and can include confusion, cognitive impairment, and abnormal movements. Diagnosis involves brain MRI and T. whipplei PCR on cerebrospinal fluid (CSF). Treatment includes antibiotics followed by long-term oral maintenance therapy. In some cases, corticosteroids may be needed, and patients should be monitored for immune reconstitution inflammatory syndrome (IRIS). Relapses may occur and require additional treatment.
Brain Abscess
Brain abscesses are localized infections within the brain. They are often caused by bacteria, such as Staphylococcus aureus. Diagnosis is made through MRI, and treatment involves antibiotics like penicillin G, metronidazole, ceftriaxone, ceftazidime, and vancomycin, based on the source of the infection. Surgical drainage, either through needle aspiration or excision, is often necessary for diagnosis and treatment, especially in traumatic or fungal cases. Treatment duration varies, with immunocompromised patients needing longer therapy.
HIV Neuropathy
HIV-related neuropathic conditions include distal symmetric peripheral neuropathy (DSPN), often caused by HIV viremia, aging, diabetes, or certain drugs. Treatment involves discontinuing neurotoxic medications, using antiretroviral therapy, and managing symptoms with drugs like gabapentin and duloxetine. Other HIV-related neuropathies include acute and chronic inflammatory demyelinating polyneuropathies, progressive polyradiculopathy, and autonomic neuropathy, though the prevalence of autonomic neuropathy has decreased in the era of antiretroviral therapy.
HIV Myopathy
HIV myopathy is a muscle weakness condition in HIV-infected individuals, often caused by older HIV medications. Treatment typically starts with glucocorticoids like prednisolone or methylprednisolone, followed by a gradual tapering of the medication. Non-responders may try methotrexate or azathioprine. Monitoring for side effects is important. Physical and speech therapy, along with dietary precautions, can also help manage the condition.
CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) is a rare type of brain lymphoma. Diagnosis involves biopsy, and treatment includes high-dose methotrexate with rituximab. Surgery is mainly for diagnosis, and clinical trials are encouraged. Consolidation therapy may involve high-dose chemotherapy or radiation. Relapse can be treated with various options.
Tuberculous Meningitis
Tuberculous meningitis is a serious brain infection linked to tuberculosis, typically affecting young children and adults with weakened immune systems. Symptoms include a stiff neck, headache, fever, and vomiting. Diagnosis is confirmed through cerebrospinal fluid tests. Early treatment with tuberculosis drugs and corticosteroids is crucial. A surgical consultation may be necessary for those with hydrocephalus (increased brain fluid) or vision issues. Patients should be closely monitored and treated with directly observed therapy for 9 to 12 months. Drug-resistant strains require different treatment regimens. Corticosteroids help manage inflammation, and surgery may be considered for certain complications.
CNS Toxoplasmosis
Toxoplasmosis is a brain infection common in immunosuppressed individuals, caused by the parasite Toxoplasma gondii. Symptoms include fever, encephalitis, and eye problems. Treatment involves drugs like sulfadiazine, pyrimethamine, and leucovorin. Corticosteroids may be used for certain symptoms. Improvement is expected in most cases, and treatment lasts about six weeks, with the possibility of long-term therapy. Primary prevention with medication is recommended for some HIV patients.
HIV Dementia
HIV-associated neurocognitive disorders (HAND), including HIV-associated dementia (HAD), involve cognitive impairments in memory, attention, and motor skills. HAD is diagnosed when cognitive deficits in two domains and daily life difficulties are evident. Screening for mild deficits is debatable. Antiretroviral therapy (ART) is the primary treatment, often leading to improvement within weeks to months. In cases with neuropsychiatric features or dementia, adjunctive medications like methylphenidate may be considered, with safety assessments and referrals as needed.
CMV Encephalitis
Cytomegalovirus (CMV) encephalitis is a serious complication often seen in AIDS patients or those with severe immune suppression, potentially leading to paralysis or fatal encephalitis. It can occur even before a significant drop in CD4 cell count. Symptoms include altered mental status, confusion, and neurological issues. Diagnosis is confirmed by detecting CMV DNA or antigen in the cerebrospinal fluid. Treatment involves dual therapy with ganciclovir and foscarnet, or alternative options if needed. Antiretroviral therapy begins after about two weeks of anti-CMV treatment, and maintenance therapy with valganciclovir continues until the CD4 count reaches ≥100 cells/microL for at least six months.
Paraneoplastic myelitis
Paraneoplastic myelitis is a diverse group of spinal cord disorders caused by mechanisms unrelated to metastases, infections, coagulopathy, or metabolic issues. It leads to rapidly progressive spastic paresis and can involve other parts of the nervous system. Commonly associated antibodies include anti-Hu, anti-CRMP5, and anti-amphiphysin antibodies, with a strong association with small cell lung cancer (SCLC) and other malignancies. Treatment focuses on removing the tumor source and suppressing the immune response. Plasma exchange or intravenous immune globulin (IVIG) may be used initially, followed by glucocorticoids, cyclophosphamide, or rituximab if needed. Early tumor identification and management can stabilize or improve the neurological syndrome.
Spinal epidural abscess
Spinal epidural abscess (SEA) is a serious spinal cord infection that can lead to severe complications or death. It can be caused by bacteria entering through various means. Prompt diagnosis with MRI is crucial. Treatment involves surgical drainage and antibiotics. Empiric antibiotics are given immediately upon suspicion, followed by tailored antibiotics once the pathogen is known. Surgery is required for certain cases, while selected patients may be managed conservatively. Treatment typically lasts four to eight weeks.
Acute Transverse Myelitis
Acute transverse myelitis (TM) is a rapid-onset immune-related spinal cord disorder often triggered by viral infections. It can lead to symptoms like weakness, sensory changes, and bladder problems. Treatment includes high-dose glucocorticoid therapy, plasma exchange in non-responsive cases, and supportive care like physical therapy and urinary retention management. Recurrence is possible, and some patients may develop multiple sclerosis, warranting chronic immunomodulatory therapy.
Viral Encephalitis
Viral encephalitis involves viral infection of the central nervous system (CNS). It often presents with altered mental status, motor or sensory deficits, behavioral and personality changes, speech and movement disorders. Viral encephalitis can be primary or post-infectious and is caused by various viruses, including herpes simplex virus type 1, St. Louis encephalitis, Japanese encephalitis, enterovirus type 71, West Nile virus, cytomegalovirus (CMV), varicella zoster virus, Epstein-Barr virus, HIV, human herpes virus-6, and Zika virus.
Autoimmune Encephalitis
Autoimmune encephalitis is an immune-mediated inflammatory brain condition, often linked with antibodies against neuronal cell surface/synaptic proteins. It encompasses a range of syndromes with diverse neuropsychiatric symptoms, including memory deficits, cognitive impairment, psychosis, seizures, abnormal movements, or coma. The condition is related to various antibodies and can be associated with different types of cancers.
Paraneoplastic Encephalitis
Paraneoplastic encephalitis is an inflammatory brain condition related to cancer. It is usually immune-mediated and often associated with antibodies against intracellular neuronal proteins. Manifestations can include limbic, brainstem encephalitis, or widespread neuraxis involvement. It frequently associates with certain autoantibodies and various types of cancer. Symptoms typically include amnesia, confusion, or seizures.
Tension Headache
Tension type headache (TTH) is the most common form of headache in the general population, characterized by mild to moderate bilateral, non-throbbing pain. It is often associated with stress and mental tension. TTH is categorized into three subtypes: infrequent episodic, frequent episodic, and chronic. Chronic TTH may be linked to stress, anxiety, and depression. Understanding the nuances of TTH, including its diagnostic approach and treatment modalities, is crucial for effective management.
Spontaneous Intracranial hypotension
Spontaneous intracranial hypotension (SIH) is a condition characterized by symptoms such as orthostatic headache, low cerebrospinal fluid (CSF) pressure, and diffuse meningeal enhancement on brain MRI. The condition often presents with a normal neurological examination and can include other symptoms related to low CSF pressure. The diagnosis and management of SIH involve specific imaging techniques and a range of treatments from conservative approaches to surgical interventions.
Idiopathic Intracranial Hypertension
This article provides a comprehensive overview of Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri. It discusses the symptoms, diagnostic procedures, and various treatment approaches for IIH, highlighting the condition's prevalence in overweight women of childbearing age and its potential for severe, disabling headaches and vision loss.
Cerebral Venous Thrombosis
This article focuses on Cerebral Venous Thrombosis (CVT), highlighting its increasing recognition due to advanced MRI technology and heightened clinical awareness. It discusses the mechanisms, risk factors, symptoms, and the crucial diagnostic procedures for CVT. The article also details the comprehensive treatment approach, which includes anticoagulation therapy and management of elevated intracranial pressure, along with long-term treatment considerations and seizure prophylaxis.
Exertional Headache
This article provides a detailed overview of headaches induced by physical exercise, exploring both primary and secondary forms. It discusses the clinical features, diagnostic procedures, and treatment options for exercise-induced headaches. The article highlights the importance of differentiating these headaches from other serious conditions through imaging and emphasizes prophylactic treatment strategies.
Temporal arteritis
This article offers a comprehensive understanding of Giant Cell Arteritis (GCA), a systemic vasculitis primarily affecting older individuals. It delves into the clinical manifestation, diagnostic criteria, and management strategies for GCA. The importance of timely diagnosis through histopathology or imaging and the critical role of glucocorticoid therapy in management are emphasized. The article also discusses treatment approaches for patients with negative biopsies and imaging, as well as strategies for managing and monitoring patients on long-term glucocorticoid therapy.
Coiatal headache
This article discusses the relatively uncommon syndrome of headaches associated with sexual activity, encompassing various types such as sexual headache, benign vascular sexual headache, and (pre)orgasmic headache. It emphasizes the importance of evaluating for potential underlying malignant causes. The article describes the characteristics of these headaches and outlines both acute and preventive treatment strategies.
Carotidynia
This article provides an overview of Carotidynia, a condition characterized by pain in the cervical carotid artery. It discusses the typical presentation of Carotidynia, including tenderness over the carotid bifurcation and findings from brain MRI and MRA. The article addresses the lack of specific treatment for Carotidynia and outlines various management strategies, including the use of NSAIDs, calcium channel blockers, steroids, and treatments for associated conditions like migraines.
Trigeminal Autonomic Cephalalgias: Focus on Cluster Headaches
This article provides a comprehensive overview of Trigeminal Autonomic Cephalalgias (TACs), with a specific focus on cluster headaches. It details the clinical features of cluster headaches, such as severe unilateral pain and autonomic symptoms, and discusses both acute and preventive treatment strategies. The article highlights the importance of timely intervention in cluster headaches to reduce the frequency and severity of attacks and explores various pharmacological and investigational neurostimulation treatments.
Migraine
This article provides an extensive overview of migraine, a disorder characterized by recurrent episodes of severe headache, often accompanied by nausea and sensitivity to light and sound. It outlines the phases of migraine, precipitating factors, and details both prophylactic and abortive treatment strategies. The article also discusses medication overuse headache and adjunctive therapies for migraine, highlighting the complexity of migraine management.
Glossopharyngeal Neuralgia
This article provides an in-depth overview of Glossopharyngeal Neuralgia (GPN), a condition characterized by paroxysmal pain in areas innervated by the glossopharyngeal and vagus nerves. It highlights the clinical similarities and differences between GPN and trigeminal neuralgia, including the common triggers and bilateral involvement in some patients. The article discusses diagnostic procedures like MRI/MRA and outlines the pharmacological therapies used for managing GPN, mirroring those for trigeminal neuralgia. Additionally, the article explores surgical treatment options for cases where medical therapy is ineffective.
Trigeminal Autonomic Cephalalgias
This article offers a detailed exploration of Trigeminal Autonomic Cephalalgias (TACs), focusing specifically on paroxysmal hemicrania. It describes the characteristics of paroxysmal hemicrania, including its symptoms, diagnostic criteria, and response to the indomethacin test. The article emphasizes the prophylactic treatment approach due to the short and intense nature of the attacks and discusses various treatment options including indomethacin, NSAIDs, calcium channel blockers, and alternative approaches like nerve blockades and occipital nerve stimulation.
Trigeminal Neuralgia
This article delves into Trigeminal Neuralgia (TN), a condition characterized by recurrent episodes of unilateral electric shock-like pain in the distribution of the trigeminal nerve. It outlines the triggers, clinical presentation, and the importance of brain MRI for diagnosis. The article discusses various pharmacological therapies, including carbamazepine, oxcarbazepine, gabapentin, and lamotrigine, as well as adjunctive therapies like baclofen and pimozole. The role of intravenous rescue therapies and the potential for surgical intervention in refractory cases are also explored.
Wernicke-Korsakoff Syndrome
This article discusses Wernicke-Korsakoff syndrome, a complication of thiamine (vitamin B1) deficiency. It describes the distinct manifestations of Wernicke encephalopathy (WE) and Korsakoff syndrome (KS), including their clinical features, risk factors, and treatment approaches. The article emphasizes the urgency of treating WE to prevent death and neurological morbidity and acknowledges the challenges in the diagnosis and treatment of these conditions.
Huntington Disease
This article provides a detailed overview of Huntington's disease (HD), an inherited progressive neurodegenerative disorder. It outlines the genetic basis of HD, its clinical features including chorea, cognitive impairment, and psychiatric symptoms, and emphasizes the lack of a cure or disease-modifying treatment. The article discusses a range of therapeutic approaches focusing on symptom management, encompassing multidisciplinary care, pharmacological treatments for various symptoms, and the importance of palliative care.
Normal Pressure Hydrocephalus
This article provides an in-depth exploration of Normal Pressure Hydrocephalus (NPH), a condition characterized by enlarged ventricular size with normal cerebrospinal fluid pressure. It differentiates NPH from non-communicating hydrocephalus and describes its classic clinical triad: dementia, urinary incontinence, and gait disturbance. The article covers diagnostic approaches, including MRI and CSF drainage tests, and discusses treatment options, primarily focusing on ventricular shunting. It also highlights potential complications associated with shunt procedures.
Dementia with Lewy Bodies
This article provides a comprehensive overview of Dementia with Lewy Bodies (DLB), the second most common type of degenerative dementia after Alzheimer's disease. It highlights the symptoms and progression of DLB, including cognitive fluctuations, visual hallucinations, Parkinsonism, and REM sleep disorders. The article emphasizes that treatment for DLB is symptomatic, focusing on specific disease manifestations, and includes both non-pharmacological and pharmacological measures. Special attention is given to the sensitivity of individuals with DLB to antipsychotic drugs and the potential severe side effects.
Parkinson Disease Dementia
This article focuses on Parkinson Disease Dementia (PDD), a common condition in patients with Parkinson's disease. It details the prevalence of PDD, particularly in older patients with prolonged motor dysfunction, and contrasts the cognitive symptoms of PDD with those of Alzheimer's disease. The article also discusses the symptomatic treatment of PDD, noting the lack of therapies that modify the disease course. It outlines medical treatments, including cholinesterase inhibitors and memantine, and advises on discontinuing medications that could impair cognition.
Corticobasal Degeneration
This article provides an in-depth look at Corticobasal Degeneration (CBD), a neurodegenerative disorder characterized by motor and gait disorders, cognitive decline, and behavioral abnormalities. It discusses the median survival rate for patients with CBD and notes the absence of effective treatments for the disease. The article outlines various non-pharmacological and pharmacological management strategies to alleviate symptoms, including physical and occupational therapy, dietary modifications, and a range of medications targeting different symptoms of CBD.
Progressive Supranuclear Palsy
This article discusses Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, a rare parkinsonian syndrome. It details the symptoms of PSP, including vertical supranuclear gaze palsy, unexplained falls, and cognitive dysfunction, and highlights the median overall survival rate post-diagnosis. The article also covers the lack of effective treatments to alter the disease's progression and outlines both non-pharmacological and pharmacological treatment approaches.
Frontotemporal Dementia
This article delves into Frontotemporal Dementia (FTD), a neurodegenerative disorder affecting the frontal and/or temporal lobes of the brain. It outlines the behavioral changes associated with FTD, discusses the lack of approved disease-modifying treatments, and reviews both pharmacological and non-pharmacological management strategies. The article emphasizes the importance of behavioral modification and structured environments, as well as pharmacologic treatments, including cholinesterase inhibitors and serotonin reuptake inhibitors.
Vascular Dementia
This article offers an in-depth analysis of vascular dementia, characterized as dementia primarily caused by cerebrovascular disease or impaired cerebral blood flow. It covers the causes, risk factors, cognitive profile, and management strategies for vascular dementia, including both non-pharmacological and pharmacological treatments. The article also discusses investigational agents with inconclusive results and is supported by references from various neurological and medical studies.
Alzheimers disease
The article provides a comprehensive overview of Alzheimer's Disease (AD), a common neurodegenerative disorder in older individuals. It discusses the characteristics, diagnostic criteria, and treatment options for AD. Key points include the identification of AD as the primary cause of dementia in the elderly, details on how to diagnose the disease, and an examination of the available treatments, focusing on cholinesterase inhibitors and memantine. The article also outlines the limitations of current therapies, emphasizing that there is no cure for AD. References from various medical studies and journals support the information provided.
Acute Dystonia
Acute Dystonia Management: This article focuses on treating acute drug-induced dystonia, a movement disorder.
Akathisia Management
Managing Akathisia: This article delves into strategies for handling akathisia, characterized by psychomotor agitation and a feeling of internal restlessness
Management of Lewy Body Dementia
Addressing Lewy Body Dementia: This article offers a comprehensive guide on managing its diverse symptoms
Nightmares
Explore effective pharmacological and non-pharmacological strategies for managing CNS-related conditions.
Tourettes Syndrome
Discover effective treatment options for Tourette's Syndrome with this detailed guide. Learn about medications such as Clonidine and Guanfacine for mild tics, and Pimozide for moderate/severe tics, including considerations for Tourette's syndrome with ADHD.
Susac Syndrome
Explore Susac's Syndrome, a rare and unique neurological disorder, with this comprehensive guide. Learn about the diagnostic triad comprising BRAO, Encephalopathy, and Hearing loss, and recognize the clinical presentation, including subacute encephalopathy and ophthalmic manifestations.
Serotonin Syndrome
Uncover the signs and management of Serotonin Syndrome with this comprehensive guide. Recognize key symptoms, from changes in mentation to motor and autonomic signs, and distinguish from other syndromes. Explore differential diagnoses such as Anticholinergic syndrome and Neuroleptic Malignant syndrome.
IV Dose Calculations
Master the art of calculating infusion rates for IV medications with this comprehensive guide. Learn essential conversion formulas, from micrograms per minute to milligrams per hour, and milligrams per hour to milliliters per hour.
multiple sclerosis management
Navigate the intricacies of Multiple Sclerosis Disease-Modifying Therapy with this in-depth follow-up protocol guide. Learn about crucial testing, including neutralizing antibodies and MX1 biological activity, for patients on interferons or Copaxone.
Hyponatremia Management
Master the intricacies of Hyponatremia Management with this comprehensive guide.
EPIDURAL ABSCESS
Unlock the key to effective Epidural Abscess treatment with this detailed guide. Delve into the antibiotic regimen, featuring Vancomycin or Nafcillin for MSSA, Linezolid, Metronidazole, and a choice between Ceftazidime or Meropenem for comprehensive coverage.
Anti Epileptic Medication Dosing
Explore optimal dosing strategies for Anti-Epileptic Medications in this detailed guide. From Lacosamide to Trileptal, Tegretol, Depakote, and Lamictal, uncover step-by-step dosage protocols over several weeks.
ADHD Management
Explore ADHD treatment options with this informative guide. Learn about dosage recommendations for Methylphenidate (Ritalin) and Dextroamphetamine (Adderall), and how they may impact tics. Discover the dosage guidelines for Strattera (Atomoxetine) to manage ADHD symptoms effectively.
Acute stroke with Atrial Fibrillation
Explore effective management strategies for acute stroke in Atrial Fibrillation among non-TPA candidates.
Subdural Hematoma
Dive into the nuances of Subdural Hematoma with this informative guide. Explore the acute, subacute, and chronic phases, and discover crucial indications for surgical evacuation. From volume and thickness considerations to midline shift and GCS score, gain insights into the decision-making process for surgical intervention.
Sub Arachnoid Hemorrhage
Unlock the complexities of Subarachnoid Hemorrhage with this detailed guide. From investigations and medical management for non-operated aneurysms to blood pressure targets and indications for coiling or clipping. Explore medication regimens, pain management strategies, and crucial details on the Hunt-Hess Grading Scale.
Anticoagulant related Intracranial Bleeds
Unlock the secrets to effective Intracranial Hemorrhage (ICH) management with this comprehensive guide. From essential stat labs for all cases to targeted interventions for IV TPA-related ICH, Warfarin-related ICH, and bleeding from anticoagulants like Direct Thrombin Inhibitors and Factor Xa Inhibitors.
Angioedema Management
Discover effective strategies for Angioedema Management in this comprehensive article. Learn vital techniques such as treating airway obstruction through intubation and utilizing Epinephrine 1:1000 injections. Explore specific medication options, including Berinert, Ecallantide, and Icatibant, with recommended dosages.
Anaphylaxis Management
Explore effective Anaphylaxis Management strategies with this informative article. Learn about the crucial role of Epinephrine 1:1000 in emergencies, along with respiratory support techniques, including oxygen administration and intubation. Dive into the specifics of medications like Albuterol, Diphenhydramine, Ranitidine, and Solumedrol for comprehensive treatment.
Status Epilepticus Management
Unlock the essential steps for effective Status Epilepticus Management with this detailed guide. From initial presentation to critical time points at 5, 20, and 40 minutes, discover the precise interventions and medications required.
MYASTHENIA GRAVIS MANAGEMENT
Explore the intricacies of Myasthenia Gravis Management with this comprehensive guide. From crucial investigations for accurate diagnosis to detailed drug regimens and overall patient care, this article covers it all.
Gilenya Protocol
Unlocking the Gilenya Protocol: A comprehensive guide to navigating the administration, precautions, and monitoring procedures associated with Gilenya, a leading treatment for multiple sclerosis.
MENINGITIS MANAGEMENT
Explore comprehensive guidelines for Meningitis Management across diverse patient profiles, including those under 50 with normal immunity, individuals above 50 with normal immunity, immunocompromised patients, and cases involving head trauma, penetration, or neurosurgery.
ENCEPHALITIS
Dive into the intricacies of Encephalitis, focusing on specific viral causes and tailored treatment approaches. Uncover detailed protocols for HSV Encephalitis, Herpes Virus 6 Encephalitis, CMV, VZV, and B Virus, along with recommendations for possible tick exposure.
MANAGEMENT OF DYSTONIA
Optimize your dystonia management with this comprehensive guide. Explore effective treatments for acute dystonia, status dystonia, tardive dystonia, and DOPA-responsive dystonia.
DYSKINESIA MANAGEMENT
Explore Effective Dyskinesia Management Strategies: From Clonazepam for Paroxysmal Non-Kinesiogenic Dyskinesia to Tegretol and Dilantin for Paroxysmal Kinesiogenic Dyskinesia, this article delves into targeted pharmaceutical interventions.
BRAIN ABSCESS
Explore effective treatment strategies for brain abscess and its unknown sources of infection. Learn about appropriate antibiotic choices based on patient allergies, including options for those allergic to penicillin.
AUTOIMMUNE ENCEPHALITIS
Unlock the complexities of Autoimmune Encephalitis with a comprehensive guide. Learn to recognize key indicators, from memory deficits to MRI abnormalities, prompting consideration of autoimmune causes.
HYPONATREMIA MANAGEMENT
Explore the fundamentals of hyponatremia management in this concise guide designed for medical students. Understand serum osmolarity, volume status, and urine sodium levels to effectively diagnose and treat this common electrolyte imbalance.